Iterion Therapeutics Initiates First-in-Class Wnt/β-Catenin Inhibitor Trial for Relapsed Osteosarcoma
Key Insights
Iterion Therapeutics (search) has dosed the first patient in a clinical study evaluating tegavivint, a first-in-class Wnt/β-catenin (search) pathway inhibitor, combined with gemcitabine for relapsed or refractory osteosarcoma.
Tegavivint is a small-molecule inhibitor of TBL1 (search) that has already demonstrated favorable tolerability and encouraging monotherapy clinical responses in hepatocellular carcinoma and desmoid tumors.
The trial targets osteosarcoma, the most common malignant bone tumor in children and adolescents, where Wnt/β-catenin (search) signaling is highly active in relapsed and metastatic disease.
Iterion Therapeutics (search) has achieved a significant clinical milestone by dosing the first patient in a study evaluating tegavivint, a first-in-class inhibitor of the Wnt/β-catenin (search) pathway, in combination with gemcitabine for patients with relapsed or refractory osteosarcoma. The trial is sponsored by Emory University and conducted at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, with support from the Peach Bowl LegACy Fund.
Novel Mechanism Targets Critical Cancer Pathway
Tegavivint represents a breakthrough approach to targeting Wnt-driven cancers through its unique mechanism of action. The drug is a small-molecule inhibitor of TBL1 (search), a transcriptional co-factor required for oncogenic β-catenin (search) signaling. By selectively disrupting the TBL1/β-catenin transcriptional complex, tegavivint promotes degradation of nuclear β-catenin and suppresses β-catenin-dependent gene transcription, effectively shutting down Wnt-driven tumor growth while avoiding the dose-limiting toxicities historically associated with upstream Wnt inhibition.
"Tegavivint represents a novel approach to targeting one of the central biological drivers of osteosarcoma," said Rahul Aras, PhD, President and CEO of Iterion Therapeutics (search). "This first patient dosed marks an important clinical milestone for a program supported by extensive biological validation and reinforces the broader value of our Wnt/β-catenin (search) platform."
Addressing Critical Unmet Need in Pediatric Oncology
Osteosarcoma is the most common malignant bone tumor in children and adolescents, with outcomes following relapse remaining poor. A growing body of research has demonstrated that Wnt/β-catenin (search) signaling is highly active in relapsed and metastatic osteosarcoma, where it is associated with tumor progression, treatment resistance, and metastasis.
"Tegavivint is uniquely positioned for osteosarcoma because it targets a pathway that is consistently active in high-risk and relapsed disease," said Thomas Cash, MD, Principal Investigator of the study at the Aflac Cancer and Blood Disorders Center and Associate Professor of Pediatrics at Emory University. "Evaluating tegavivint in combination with gemcitabine allows us to build on a strong scientific foundation as we seek to improve outcomes for patients with limited treatment options."
Strong Clinical Foundation and Regulatory Support
Tegavivint has already demonstrated favorable tolerability, pharmacodynamic activity, and encouraging monotherapy clinical responses in Company-sponsored clinical trials in hepatocellular carcinoma and desmoid tumors, two diseases driven by aberrant Wnt/β-catenin (search) signaling. Additionally, a Children's Oncology Group (COG)-led study conducted through the National Cancer Institute has established the safety of tegavivint across a broad pediatric population, providing a strong foundation for advancement into disease-focused combination studies in osteosarcoma.
The drug has received both Orphan Drug Designation and Pediatric Rare Disease Designation from the U.S. Food and Drug Administration for the treatment of osteosarcoma, highlighting the regulatory recognition of its potential therapeutic value in this rare pediatric cancer.
Platform Potential for Wnt-Driven Cancers
Iterion Therapeutics (search) is positioned at the forefront of Wnt/β-catenin (search) drug development with tegavivint being the first and only small-molecule inhibitor of TBL1 (search) to demonstrate tolerability and monotherapy clinical activity in complex solid tumors. The company is advancing a focused clinical strategy anchored by its lead program in hepatocellular carcinoma, with expansion into additional Wnt-driven cancers, including pediatric and rare oncology indications where Wnt/β-catenin signaling represents a validated disease driver.